Hans de Haard
Co-Founder & Member of Board AdvisorsProf. Hans de Haard, Ir, Ph.D. is a Member of Board Advisors at argenx SE. Prof. de Haard was a Senior Advisor at BioGeneration Ventures B.V. He is a Co-Founder of argenx SE and had been the Chief Scientific Officer of argenx SE since July 01, 2008 until January 2023 and served as its Director of Management Board since July 1, 2008. Prof. de Haard serves as Scientific Director of Ablynx nv. Prof. de Haard served as Director of Technology Development of Ablynx nv since 2002 and served as its Senior Director of Discovery Reseach. He served as Manager in Functional Biomolecules group of Unilever Research Laboratories in Vlaardingen. He was responsible for setting up the Nanobody® discovery engine and he introduced the VHH formatting, which turned out to be the major advantage of Ablynx's Nanobody® platform. He was closely involved in the development of the Nanoclone® methodology based on B cell selection. He was in charge of research program within Unilever concerning applications of camelid single-domain antibodies for several Unilever consumer product groups. He served as Project Leader in Antibody Engineering of Organon. During his career he has discovered therapeutic antibody leads against over 10 therapeutic targets, several of which are now in the preclinical and clinical stage. He holds a Master of Science degree in Biochemistry and a PhD in Molecular Immunology from the University of Maastricht. He is a professor of immunology at the university of Utrecht.
Positions
- Company Nameargenx SEStock CodeARGXPositionCo-Founder & Member of Board AdvisorsColleagues
- TVTimothy Van HauwermeirenCo-Founder & Non-Independent Non-Executive Chairman of the Board
- KMKaren MasseyCEO & Executive Director
- KGKarl GubitzChief Financial Officer
- PUPeter UlrichtsChief Scientific Officer
- MMMalini MoorthyGeneral Counsel & Corporate Secretary
- AAAnthony A. RosenbergIndependent Vice Chairman
- ACAna CespedesIndependent Non-Executive Director
